FITZGERALD EDWARD M
CIK: 0001242993
Associated companies
Transaction History
| PBLS | ▼ Sell | Other | 5,539 | — | 6/11/2026 | View on chart |
| PBLS | ▼ Sell | Other | 5,271 | — | 6/11/2026 | View on chart |
| PBLS | ▼ Sell | Other | 3,878 | — | 6/11/2026 | View on chart |
| PBLS | ▼ Sell | Other | 5,539 | — | 6/11/2026 | View on chart |
| PBLS | ▼ Sell | Other | 5,271 | — | 6/11/2026 | View on chart |
| PBLS | ▼ Sell | Other | 3,878 | — | 6/11/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial
Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.
Parabilis Medicines starts dose‑ranging cohort of Zolucatetide trial. Parabilis Medicines has begun a dose‑ranging cohort of its Zolucatetide program in patients with familial adenomatous polyposis, extending its Phase 1/2 clinical study. The new cohort will provide additional safety and efficacy data to help define the optimal dose for this indication. This development comes as the stock trades near a well‑tested support level and analysts maintain a target price near the top of its 52‑week range.